Jaap Verweij, M.D., PhD is a Professor of Medical Oncology and Chair of the Department of Medical Oncology of the Erasmus University Medical Centre in Rotterdam, The Netherlands.
Prof. Verweij graduated in 1978 as a medical doctor at the Free University Hospital in Amsterdam. He joined the medical staff of Medical Oncology at the Daniel den Hoed Cancer Center in Rotterdam in 1984 and in 1986 he obtained his PhD. He was appointed Professor of Medical Oncology in 1998.
His main scientific interests are new drug development, including the performance of clinical Phase I and early Phase II trials, and the inclusion of pharmacokinetics and pharmacodynamics in these studies. He also has a major interest in the design aspects of early clinical studies.
Beside his clinical activities Prof Verweij has been the Chairman of the Early Clinical Studies Group of the European Organisation for Research and Treatment of Cancer (EORTC) from 1993-1996, Chairman of the EORTC Soft Tissue and Bone Sarcoma Group from 1996-1999, Chairman of the EORTC New Treatment Committee, the EORTC New Drug Advisory Committee, and Vice-President of EORTC. He has also been President of the Connective Tissue Oncology Society (CTOS), Chairman of the RECIST working group, and Chairman of the Scientific Council of the Dutch Cancer Foundation.
Prof. Verweij is an ESMO Faculty Member for Principles of Clinical Trials and Systemic Therapy. Prof Verweij has recently been editor of the European Journal of Cancer and is still associate editor of the Journal of Clinical Oncology. He currently serves on the Board of the Dutch Cancer Foundation.
He has authored or co-authored over 700 papers on various aspects and has given numerous lectures on a variety of topics at international meetings.